Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2021 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $9.600-$9.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.520. The company issued revenue guidance of $93.80 billion-$94.60 billion, compared to the consensus revenue estimate of $91.30 billion.Johnson & Johnson also updated its FY21 guidance to $9.60-9.70 EPS.
Shares of JNJ stock traded up $0.96 during midday trading on Thursday, hitting $170.45. 237,056 shares of the company were exchanged, compared to its average volume of 6,223,537. Johnson & Johnson has a 52 week low of $133.65 and a 52 week high of $173.65. The stock has a market cap of $448.86 billion, a price-to-earnings ratio of 30.07, a P/E/G ratio of 2.71 and a beta of 0.71. The firm has a 50 day moving average price of $167.25. The company has a quick ratio of 1.04, a current ratio of 1.28 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 20th. The company reported $2.48 EPS for the quarter, beating the consensus estimate of $2.29 by $0.19. The company had revenue of $23.31 billion for the quarter, compared to the consensus estimate of $22.54 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 17.95%. The firm’s revenue for the quarter was up 27.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.67 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 9.51 earnings per share for the current fiscal year.
A number of brokerages have issued reports on JNJ. Morgan Stanley assumed coverage on shares of Johnson & Johnson in a research report on Friday, May 28th. They set an overweight rating and a $187.00 target price on the stock. Credit Suisse Group set a $193.00 price objective on Johnson & Johnson and gave the stock a buy rating in a research note on Monday, June 7th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $190.38.
An institutional investor recently bought a new position in Johnson & Johnson stock. OLD Mission Capital LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 2,432 shares of the company’s stock, valued at approximately $362,000. Hedge funds and other institutional investors own 66.60% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: What is a support level?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.